UK ADHD Therapeutics Market Analysis Report 2022 to 2030

UK ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

The UK Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $769 Mn in 2022 to $1,179 Mn in 2030 with a CAGR of 5.5% for the year 2022-30 as there is an increase in awareness in the diagnosis and treatment for ADHD as well as availability of new therapeutic options in UK. The UK ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Colonis Pharma, Shire, and Advanz Pharmaceuticals are the key players in the market.

ID: IN10GBPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Parul Choudhary

Buy Now

UK Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The UK Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $769 Mn in 2022 and is projected to reach $1,179 Mn in 2030, exhibiting a CAGR of 5.5% during the forecast period. The budgeted amount for health care expenditure in the UK in 2023 is $223.80 Bn. According to the 2023 Global Medical Trends Survey, the expense trend for healthcare benefits increased from 8.2% in 2021 to an overestimated 8.8% in 2022. Even in Europe, where expense increases have historically been much smaller, the trend is at record levels. The average growth rate in Europe is predicted to climb to 8.6% in 2023 from 8.0% in 2022. Private medical insurance costs in the UK are predicted to rise by 8.8% in 2023, which is considerably higher than this year's 6.8% increase but only slightly above the average for Europe. The healthcare benefit cost in the UK is projected to grow from 6.8% in 2022 to 8.8% in 2030 according to the Global medical trends survey.

ADHD is characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity that hinders functioning or growth. Inattention, hyperactivity, and impulsivity are the three kinds of symptoms that people with ADHD frequently experience. The estimated range of frequency on a global scale is 2-7%, with an average of 5%. In a study of 10,438 kids in the UK between the ages of 5 and 15, it was discovered that 0.85% of females and 3.62% of boys had ADHD. ADHD changes with age, but the majority, approximately 65%, maintain some impairments in adulthood. Recent press in the UK has focused on the absence of distinct diagnostic pathways and support for ADHD, especially for women and girls. The prevalence of ADHD in adults is typically stated to range from 2.5% to 4%, though this estimate is thought to be conservative. Only 10 to 20 % of people with ADHD will receive treatment. Executive function issues are a daily struggle for people with ADHD, compromising their effectiveness at work. This is due to the fact that executive function deficiencies have a direct impact on a person's capacity to initiate and complete tasks, plan and prioritize work, remember crucial information, avoid distractions, and control impulsivity.

A combined approach of therapy and medication is frequently the most effective treatment for ADHD. Five different kinds of medications, including methylphenidate, lisdexamfetamine, dexamfetamine, atomoxetine, and guanfacine, are approved for the treatment of ADHD. The drug most frequently prescribed for ADHD is methylphenidate. It is a member of the class of drugs known as stimulants, which increase brain activity, especially in regions involved in attention and behavior control. Methylphenidate may be prescribed to adults, adolescents, and kids older than five who suffer from ADHD.

There are several stimulants and one non-stimulant among the medications approved for ADHD in the UK. The first medications that are typically recommended are the stimulant methylphenidate and, on certain occasions, the more recent amphetamine-based drug lisdexamfetamine (Elvanse). To find the ideal dosage, the medication's dose may need to be adjusted frequently in the beginning (titrated), and regular side-effect monitoring is also required. Atomoxetine (Strattera), a medication that differs from stimulants in its mode of action and is approved to treat ADHD, is referred to as a non-stimulant medicine. Atomoxetine has the benefit of producing steady 24-hour symptom control if it works, which may mean fewer issues in the evening when the stimulants tend to wear off. However, atomoxetine takes some time to function, so more patience is needed than with stimulant medications.

uk attention deficit hyperactivity disorder therapeutics market analysis

Market Dynamics

Market Growth Drivers

In the UK, there has been an increase in the number of individuals seeking an assessment and treatment for ADHD. Media coverage, advocacy organizations, and educational efforts have all contributed to this rise in awareness.

Over the past few decades, the prevalence of ADHD has significantly increased in the UK. The prevalence of ADHD in adolescents aged 5 to 15 has risen, from 1.5% in 1999 to 5.2% in 2020, according to the NHS. The UK ADHD therapeutics market has expanded as a result of this increase in prevalence.

Recent years have seen substantial improvements in the management of ADHD, including the introduction of new medications and non-pharmacological interventions like Cognitive Behavioral Therapy (CBT). These developments have expanded the choices for managing ADHD, which has fueled the UK ADHD therapeutics market's expansion.

Market Restraints

Despite increased awareness, ADHD still carries a lot of stigma in the UK, which can make it challenging for patients to get a diagnosis and initiate therapy. By lowering the demand for ADHD treatments, can restrain the UK ADHD therapeutics market's expansion.

Despite the fact that most ADHD medications are regarded as safe and successful, there are still certain concerns about their possible side effects, especially in children. The decreased demand for ADHD medicines as a result of these concerns regarding safety may restrict the UK ADHD therapeutics market expansion.

While medication is still a crucial part of treating ADHD, non-pharmacological treatments like CBT and mindfulness-based therapies are becoming more and more competitive. Some patients might favor these interventions, which could restrain the market expansion of ADHD drugs in the UK.

Competitive Landscape

Key Players

Shire (GBR)- The medication Elvanse for attention deficit hyperactivity disorder (ADHD) from Shire has been approved for use in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the single daily dose long-acting treatment, the first stimulant prescription drug to be introduced in Europe, for this behavioral psychiatric disorder that is believed to affect 3.62% of boys and 0.85% of girls in the UK between the ages of five and fifteen.
Colonis Pharma (GBR)- Colonis Pharma has received approval from the UK's MHRA to treat sleep-onset insomnia in children and teenagers with ADHD.
Pharmagona (GBR)
Curium Pharma (GBR)
Amaxa Pharma (GBR)
Bohemia Pharmaceuticals (GBR)
Advanz Pharmaceutical
Highland Therapeutics
Janssen Pharmaceuticals
NEOS Therapeutics
Noven Pharmaceuticals

Healthcare Policies and Regulatory Landscape

The UK government organization known as the Medicines and Healthcare products Regulatory organization (MHRA) is in charge of making sure that drugs, medical equipment, and blood and tissue components are safe for use by the general public. In order to ensure that they adhere to strict safety, quality, and efficacy standards, it controls medications and medical devices in the UK. In the UK, the MHRA is in charge of overseeing every stage of the life cycle of pharmaceuticals and medical devices, from clinical trials and manufacturing to marketing and post-market monitoring. The organization was established as a result of the 2003 merging of the Medical Devices Agency (MDA) and the Medicines Control Agency (MCA), as well as the 2013 edition of the National Institute for Biological Standards and Control. (NIBSC). Its duties also include supervising UK-notified organizations, controlling clinical trials, ensuring that medicines and medical devices are used according to regulations, and providing technical and regulatory guidance for these goods.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Insights10 will provide you with the reports within 10 key parameters which are:

Market Overview
Market Growth Drivers & Restraints
Epidemiology of Disease Type
Market Segmentation
Market Share
Competitive Landscape
Key Company Profiles
Healthcare Policies & Regulatory Framework
Reimbursement Scenario
Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

Establishing market drivers and trends
Analyzing the regulatory landscape to understand future growth
Market Segment based analysis to obtain revenue/volume
Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.